淋巴细胞抗原6复合物E的表达与POF方案治疗晚期胃癌疗效的相关性分析  

Correlative analysis of the expression of LY6E with the efficacy of POF regimen for advanced gastric cancer

作　　者：王少开 左云[1] 梁素莹 倪晨 Wang Shaokai;Zuo Yun;Liang Suying;Ni Chen(Oncology Department,the Affiliated Zhangjiagang Hospital of Soochow University,Jiangsu Zhangjiagang 215600,China)

机构地区：[1]苏州大学附属张家港医院肿瘤科,江苏张家港215600

出　　处：《现代肿瘤医学》2020年第17期3020-3023,共4页Journal of Modern Oncology

基　　金：张家港市青年科技项目(编号:ZJGQNKJ201806)。

摘　　要：目的:探讨晚期胃癌患者中淋巴细胞抗原6复合物E(LY6E)的表达与"紫杉醇脂质体+奥沙利铂+氟尿嘧啶"(POF)方案化疗疗效的关系。方法:收集45例一线接受POF化疗的晚期胃癌患者的临床、病理资料,采用免疫组化法检测其LY6E的表达情况,计算客观有效率(ORR)和疾病控制率(DCR),统计分析LY6E的表达与胃癌患者临床病理特征、近期疗效及临床受益率的关系。结果:45例患者中,LY6E的阳性率为71.1%。未分化-低分化腺癌LY6E的阳性表达率显著高于中-高分化腺癌(78.9%vs 28.6%,P<0.05)。45例患者ORR为31.1%,DCR为55.6%,临床受益率为40.0%。与LY6E(-)患者相比,LY6E(+)患者的ORR、DCR和临床受益率均显著降低(ORR:18.8%vs 61.5%;DCR:43.8%vs 84.6%;临床受益率:28.1%vs 69.2%)(P<0.05)。LY6E的表达与POF方案所致化疗毒副反应无显著相关性(P>0.05)。结论:LY6E与晚期胃癌分化程度相关,晚期胃癌患者中LY6E的表达可能成为预测POF方案化疗敏感性的新指标,并有可能成为胃癌治疗潜在的新靶点。Objective:To investigate the correlation of lymphocyte antigen 6 complex,locus E(LY6 E)expression with the efficacy of"taxol liposome+oxaliplatin+fluorouracil"(POF)for advanced gastric cancer.Methods:45 patients with advanced gastric cancer who were treated with POF as first line therapy were enrolled in the present study,and the clinical data and pathological samples were collected.The expression of LY6 E was detected by immunohistochemical staining.The objective response rate(ORR)and disease control rate(DCR)were calculated.The relationship of LY6 E expression with clinical data,therapeutic efficacy,clinical benefit response were analyzed.Results:The positive rate of LY6 E in the total 45 patients was 71.1%,and the positive rate in undifferentiated or poorly differentiated patients was significantly higher than moderately or well differentiated patients(78.9%vs 28.6%,P<0.05).Total ORR,DCR and the clinical benefit response rate were 31.1%,55.6%and 40.0%,respectively.ORR,DCR and the clinical benefit response rate of patients with positive LY6 E were significantly lower than the patients with negative LY6 E expression(ORR:18.8%vs 61.5%,DCR:43.8%vs 84.6%,clinical benefit response rate:28.1%vs 69.2%,P<0.05).No significant correlation was detected between LY6 E expression and the incidence of POF regimen induced adverse reactions(P>0.05).Conclusion:LY6 E is related to the histology grade of advanced gastric cancer.Patients with negative LY6 E might get more benefit from POF therapy,and LY6 E might become a new novel predictor of the therapeutic efficacy,prognosis and a potential therapeutic target of advanced gastric cancer.

关 键 词：LY6E POF方案 化疗 晚期胃癌 化疗疗效 

分 类 号：R735.2[医药卫生—肿瘤]